Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

The shares closed down nearly 12% after CVS Health's revelation and Lilly's announcement that, despite a 45% surge in first-quarter revenues driven by Zepbound (tirzepatide) and diabetes ...

Meanwhile, the Danish drugmaker was also bolstered by the decision by pharmacy benefit manager (PBM) CVS Health to remove Zepbound but retain Wegovy on its formulary of reimbursed medicines.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

The Siren’s Curse left riders in a vertical position for about 10 minutes on June 28, the Akron Beacon Journal reported.